Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Healthy, based on medical examination at inclusion~* Male or female subjects, aged between 18 and 55 years~* Willing and likely to be able to comply with the trial procedures~* Prepared to grant authorized persons access to their medical records~Additional inclusion criterion for BCG-non-vaccinated subjects:~* BCG-non-vaccinated (i.e., absence of a BCG-scar)~* Negative Mantoux skin test~Additional inclusion criterion for BCG-vaccinated subjects:~* BCG-vaccinated (i.e., presence of a BCG-scar)~Exclusion Criteria:~* History of TB or known exposure to TB~* Radiological findings on chest X ray compatible with previous or current infection with tuberculosis~* Positive QuantiFERON® TB-Gold test Evidence of previous, current or latent tuberculosis~* Evidence of previous, current or latent tuberculosis~* History of severe organ-system diseases~* Known hypersensitivity to any of the vaccine components~* History of allergic disorders~* Vaccinated with other vaccine within 3 months before first vaccination~* Congenital and/or acquired immune diseases~* Administration of systemic immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulin) within 3 months before the first vaccination (topical steroids not included)~* Autoimmune diseases~* HIV, HBV and HCV sero-positive~* Established diagnosis of a neurological or neuromuscular disease, and specifically any history of abnormality with respect to sense of smell (olfactory nerve dysfunction), or previous or current facial nerve paralysis~* Congenital or acquired abnormalities or disorders related to nasal and nasopharyngeal cavities~* Current use of any medication taken through the nasal/inhalatory route including cocaine or other drugs~* Laboratory parameters outside of normal ranges considered clinically significant~* Pregnant according to urine pregnancy test~* Females not willing to use contraceptives or who are breastfeeding~* Intake of trial medication in other clinical trials within 6 months of the first vaccination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 100 ug H1 antigen alone in BCG naive subjects
- 2 (Type: EXPERIMENTAL): 100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
- 3 (Type: EXPERIMENTAL): 50 ug H1 antigen in BCG immunized subjects
- 4 (Type: EXPERIMENTAL): 50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
- 5 (Type: EXPERIMENTAL): 100 ug H1 antigen in BCG immunized subjects
- 6 (Type: EXPERIMENTAL): 100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues